Logo-bi
Yadollah Omidi (Pharm.D., Ph.D.)
Editor-in-Chief
Nova Southeastern University, Fort Lauderdale, Florida, USA

Professor Yadollah Omidi obtained his pharmacy doctorate (Pharm.D.) degree from Tabriz University of Medical Sciences (TUOMS), Tabriz, Iran (1991), and his Ph.D. degree in the field of brain drug delivery and targeting, “Blood-brain barrier: studies of novel cell-based in vitro models and carrier-mediated transporters” from Cardiff University, Cardiff, UK (2003). From Dec. 2002 to July 2004, he worked as a postdoctoral research associate, studying gene-based nanomedicines and toxicogenomics at the Welsh School of Pharmacy, Cardiff University. In 2005, Dr. Omidi founded the Research Center for Pharmaceutical Nanotechnology (RCPN) at TUOMS - the first national center for nanomedicine research. Under his directorship, RCPN has been ranked as the national center of excellence for pharmaceutical/biomedical research (2008-2011, 2013). In 2008, he founded the School of Advanced Biomedical Sciences at TUOMS. He acted as the director of RCPN until July 2011 when he moved to the US to work at the University of Pennsylvania (UPenn). His research activities are focused on different areas of pharmaceutical sciences particularly targeted therapeutics such as multifunctional nanomedicines and theranostics. As of 2003, he has published over 310 papers in peer-reviewed international journals. Dr. Omidi is the author of 30 book chapters. His works have been cited over 10550 times with the h-index of 56 and i10-index of 207. He has over 20 years of experience in pharmacy and medical schools, teaching different subjects (Pharmaceutics, Biopharmaceutics, Pharmacogenetics, Pharmaceutical Nanotechnology, and Pharmaceutical Biotechnology) and supervising M.Sc., Pharm.D., M.D., and Ph.D. students. In 2011, Dr. Omidi founded “BioImpacts” which is an international peer-review multidisciplinary access free-publish free journal for publication of biomedical and pharmaceutical research - a publication platform for bench-to-bedside research. Professor Omidi also acts on the editorial board of several journals, including BiologicalsBMC Pharmacology and Toxicology, Nanomedicine. In 2011, he joined the Ovarian Cancer Research Center (OCRC), Perelman School of Medicine, University of Pennsylvanian (Philadelphia, USA) as a Visiting Associate Professor to undertake translational research toward the development of multifunctional nanomedicines and theranostics for targeted therapy of ovarian cancer with a particular focus on targeting of the tumor microenvironment. Follow Professor Y. Omidi's publications through  Google Scholar; PubMed; Scopus ID: 6508117068; and ORCID: 0000-0003-0067-2475. At the moment, he is working as a full professor at Nova Southeastern University College of Pharmacy.


As a peer-reviewed international open-access journal, BioImpacts publishes articles on basic and translational aspects of pharmaceutical and biomedical sciences and provides free editing services. 
Acceptance rate: 24%
First decision: 2-3 days  
Final decision:
3-6 weeks 
Publication fee: Free of charge